Format

Send to

Choose Destination
Br J Cancer. 2004 Jan 12;90(1):189-93.

G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis.

Author information

1
Département de Biologie Oncologique, Centre Régional de Lutte Contre le Cancer, René Gauducheau, boulevard Jacques Monod, 44805 Saint Herblain, France. p-jezequel@nantes.fnclcc.fr

Abstract

This study screened large cohorts of node-positive and node-negative breast cancer patients to determine whether the G388R mutation of the FGFR4 gene is a useful prognostic marker for breast cancer as reported by Bange et al in 2002. Node-positive (n=139) and node-negative (n=95) breast cancer cohorts selected for mutation screening were followed up for median periods of 89 and 87 months, respectively. PCR - RFLP analysis was modified to facilitate molecular screening. Curves for disease-free survival were plotted according to the Kaplan - Meier method, and a log-rank test was used for comparisons between groups. Three other nonparametric linear rank-tests particularly suitable for investigating possible relations between G388R mutation and early cancer progression were also used. Kaplan - Meier analysis based on any of the four nonparametric linear rank tests performed for node-positive and node-negative patients was not indicative of disease-free survival time. G388R mutation of the FGFR4 gene is not relevant for breast cancer prognosis.

PMID:
14710228
PMCID:
PMC2395301
DOI:
10.1038/sj.bjc.6601450
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center